Skip to Main Content

Author Details

Jun Qi
Dana-Farber Cancer Institute
2010
132
52
Antoine Forget (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36894709Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection.Nat Genet2023
37957169A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeutics.Nat Commun2023
37541244Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.Cancer Cell2023
37637739Manipulating Tyrosine Phosphorylation by Heterobifunctional Small Molecules.ACS Cent Sci2023
37075745Epigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1-EEF1A1 Axis.Adv Sci (Weinh)2023
37163075Acetyl transferase EP300 deficiency leads to chronic replication stress mediated by defective fork protection at stalled replication forks.bioRxiv2023
37461690SALL4B, not targeted by IMiD, is important for SALL4-mediated tumorigenesis.bioRxiv2023
36780189BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.Clin Cancer Res2023
36909530BRD9-SMAD2/3 orchestrates stemness and tumorigenesis in pancreatic ductal adenocarcinoma.bioRxiv2023
36824856Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degraders.bioRxiv2023
34341479Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy.Leukemia2022
35363464Exploring Methods of Targeting Histone Methyltransferases and Their Applications in Cancer Therapeutics.ACS Chem Biol2022
35681054SMARCE1 deficiency generates a targetable mSWI/SNF dependency in clear cell meningioma.Nat Genet2022
359415251,4-Dihydropyridinebutyrolactone-derived ring-opened ester and amide analogs targeting BET bromodomains.Arch Pharm (Weinheim)2022
35867655Bivalent BET Bromodomain Inhibitors Confer Increased Potency and Selectivity for BRDT via Protein Conformational Plasticity.J Med Chem2022
36305736BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma.Cancer Discov2022
35975457Aberrant Cholesterol Metabolism and Wnt/β-Catenin Signaling Coalesce via Frizzled5 in Supporting Cancer Growth.Adv Sci (Weinh)2022
35226736BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.Blood2022
35217626A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia.Proc Natl Acad Sci U S A2022
34932262Dihydropyridine Lactam Analogs Targeting BET Bromodomains.ChemMedChem2022
34772733EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma.Cancer Discov2022
33460788Brd4 participates in epigenetic regulation of the extinction of remote auditory fear memory.Neurobiol Learn Mem2021
33872011Development of Dimethylisoxazole-Attached Imidazo[1,2-<i>a</i>]pyridines as Potent and Selective CBP/P300 Inhibitors.J Med Chem2021
33730585Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.Cell Rep2021
34434504Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.Oncotarget2021
34593523Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy.Cancer Res2021
34107377The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.Neoplasia2021
34037670Bromodomain protein BRD4 directs and sustains CD8 T cell differentiation during infection.J Exp Med2021
34358447ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency.Mol Cell2021
34258103Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma.Blood Cancer Discov2021
33972779Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence.Nat Genet2021
32559499Peptide-Based PROTAC: The Predator of Pathological Proteins.Cell Chem Biol2020
31691152BET bromodomain inhibition suppresses adipogenesis in mice.Endocrine2020
31744829 <i>In Vivo</i> Epigenetic CRISPR Screen Identifies <i>Asf1a</i> as an Immunotherapeutic Target in <i>Kras</i>-Mutant Lung Adenocarcinoma.Cancer Discov2020
32832623Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4<sup>+</sup> T cells ex vivo.Sci Adv2020
32661245High-performance CRISPR-Cas12a genome editing for combinatorial genetic screening.Nat Commun2020
32826232The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies.Cancer Discov2020
32730819BET proteins inhibitor JQ-1 impaired the extinction of remote auditory fear memory: An effect mediated by insulin like growth factor 2.Neuropharmacology2020
32646968Epigenetic CRISPR Screens Identify <i>Npm1</i> as a Therapeutic Vulnerability in Non-Small Cell Lung Cancer.Cancer Res2020
32393766Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer.Nat Commun2020
32407673Using Chemical Epigenetics to Target Cancer.Mol Cell2020
32516588Selective Targeting of Different Bromodomains by Small Molecules.Cancer Cell2020
30279226Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.Blood2019
31494268Diversified Application of Barcoded PLATO (PLATO-BC) Platform for Identification of Protein Interactions.Genomics Proteomics Bioinformatics2019
31260717Maintenance and enhancement of human peripheral blood mobilized stem/progenitor cell engraftment after ex vivo culture via an HDACi/SALL4 axis (3465).Exp Hematol2019
31285436Chemical genomics reveals histone deacetylases are required for core regulatory transcription.Nat Commun2019
31395336FRK suppresses human glioma growth by inhibiting ITGB1/FAK signaling.Biochem Biophys Res Commun2019
31111916A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.Neuro Oncol2019
31085176BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models.Cancer Cell2019
30962579Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma.Leukemia2019
  • 1 - 50 of 132

Recommended Authors

Yunpeng Gao
University of Texas Southwestern Medical Center at Dallas
Career Start Year 2017
Number of shared co-authors 0
Diana Resetca
University of Toronto
Career Start Year 2013
Number of shared co-authors 1
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 2
Rahul K Kollipara
McDermott Center for Human Growth and Development.
Career Start Year 2010
Number of shared co-authors 0
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 6
Ganiraju C Manyam
the University of Texas MD Anderson Cancer Center
Career Start Year 2009
Number of shared co-authors 3
Benjamin G Barwick
Emory University School of Medicine
Career Start Year 2009
Number of shared co-authors 4
Daniel J Coleman
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2007
Number of shared co-authors 0
Leigh Ellis
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 2007
Number of shared co-authors 7
James R Whittle
Walter and Eliza Hall Institute of Medical Research
Career Start Year 2006
Number of shared co-authors 0
Yue Lu
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 3
Christopher A Bristow
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 6
No??l J-M Raynal
Sainte-Justine University Hospital Research Center
Career Start Year 2005
Number of shared co-authors 0
Anderly C Chueh
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 0
Michele Ceribelli
National Center for Advancing Translational Sciences
Career Start Year 2004
Number of shared co-authors 5
Justin Cidado
Oncology R&D
Career Start Year 2003
Number of shared co-authors 3
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 5
Stefan Kubicek
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences
Career Start Year 2003
Number of shared co-authors 11
Ernesto Guccione
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Career Start Year 2001
Number of shared co-authors 9
Anastasia Wyce
Collegeville
Career Start Year 2001
Number of shared co-authors 2
Viktoria Marquardt
German Cancer Research Center (DKFZ)
Career Start Year 2001
Number of shared co-authors 4
Mariano J Alvarez
Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center
Career Start Year 2000
Number of shared co-authors 4
Andrea Local
Oncogenesis Thematic Research Center
Career Start Year 1999
Number of shared co-authors 0
Alex Kentsis
Memorial Sloan-Kettering Cancer Center
Career Start Year 1998
Number of shared co-authors 10
Paul Yenerall
McDermott Center for Human Growth and Development, UT Southwestern Medical Center
Career Start Year 1997
Number of shared co-authors 0
Krister Wennerberg
University of Copenhagen
Career Start Year 1994
Number of shared co-authors 9
Rab K Prinjha
Medicines Research Centre
Career Start Year 1994
Number of shared co-authors 7
Ricky W Johnstone
The University of Melbourne
Career Start Year 1990
Number of shared co-authors 5
Kristian Helin
The Institute of Cancer Research
Career Start Year 1988
Number of shared co-authors 7
Ralf Kittler
McDermott Center for Human Growth and Development.
Career Start Year 1984
Number of shared co-authors 3

Collaborators

James E Bradner
Co-authored papers 67
Kimberly Stegmaier
Dana-Farber Cancer Institute
Co-authored papers 11
Kenneth C Anderson
Dana Farber Cancer Institute
Co-authored papers 9
Nathanael S Gray
Harvard Medical School
Co-authored papers 7
William A Weiss
University of California san francisco
Co-authored papers 6
Mousheng Xu
Co-authored papers 6
Giovanni Roti
University of Parma
Co-authored papers 6
Gabriela Alexe
Dana-Farber Cancer Institute
Co-authored papers 5
David E Root
Broad Institute of Harvard and MIT
Co-authored papers 5
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Co-authored papers 4
Alexander J Federation
Co-authored papers 4
Rameen Beroukhim
Co-authored papers 4
Sheue-Yann Cheng
National Cancer Institute, National Institutes of Health
Co-authored papers 4
Scott A Armstrong
Boston Children's Hospital
Co-authored papers 4
John G Doench
Co-authored papers 4
Myles Brown
Co-authored papers 4
Pratiti Bandopadhayay
Co-authored papers 4
Sirano Dhe-Paganon
Dana-Farber Cancer Institute
Co-authored papers 3
Angela Su
The Broad Institute of MIT and Harvard
Co-authored papers 3
Stefan Knapp
Institute of Pharmaceutical Chemistry, Goethe University
Co-authored papers 3
Alex Look
Dana-Farber Cancer Institute
Co-authored papers 3
Glenn S Cowley
Broad Institute of Harvard and MIT
Co-authored papers 3
Francisca Vazquez
Broad Institute of MIT and Harvard
Co-authored papers 3
Alexandre Puissant
Universite de Paris, INSERM, CNRS
Co-authored papers 3
Daniel G Tenen
Harvard Stem Cell Institute, Harvard Medical School
Co-authored papers 3
Federica Piccioni
Co-authored papers 3
Richard Koche
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Christopher F Bassil
Duke University School of Medicine Durham
Co-authored papers 3
Bradley E Bernstein
Broad Institute of MIT and Harvard
Co-authored papers 3
Stuart L Schreiber
Broad Institute
Co-authored papers 2
Release 1.2